EVENTS · ASPE
PEERS
EARNINGS
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company developing personalized cell therapies for neurodegenerative diseases. Its platform uses a patient’s own cells to create induced pluripotent stem cell-derived neuronal products, supporting an autologous approach designed to address neurological conditions at the individual level. The company’s lead product candidate, sasineprocel, is an investigational single-dose therapy composed of dopaminergic neuronal precursor cells for Parkinson’s disease. Aspen Neuroscience focuses on advancing cell-based treatments through clinical development, combining stem cell biology, neuroscience, cellular manufacturing, and precision medicine. Its work serves the biopharmaceutical and healthcare sectors, with particular relevance to patients and clinicians seeking alternatives for disorders involving the loss or dysfunction of specific brain cells. Headquartered in San Diego, California, Aspen Neuroscience represents the emerging regenerative medicine segment, where biotechnology companies develop patient-specific therapies intended to replace damaged cells and restore neurological function.